Literature DB >> 1163426

Hemodynamic and metabolic effects of isosorbide dinitrate in chronic congestive heart failure.

R Gray, K Chatterjee, J K Vyden, W Ganz, J S Forrester, H J Swan.   

Abstract

To assess the potential beneficial effects of a nonparenteral vasodilator, sublingual isosorbide dinitrate (5 to 15 mg.) was administered in 12 patients with chronic congestive heart failure refractory to conventional therapy. Hemodynamic measurements were performed before and at 15 minute intervals after drug administration for 90 minutes. Venous capacitance was measured at 5 minute intervals. Myocardial metabolism was also studied in five patients before and after drug administration. Hemodynamic effects were characterized by a modest decrease in mean arterial pressure (85 +/- 3 to 78 +/- 2 [S.E.M.] mm. Hg) and substantial decrease in right atrial (10 +/- 1 to 6 +/- 1), pulmonary arterial (39 +/- 4 to 30 +/- 4) and pulmonary capillary wedge pressures (28 +/- 2 to 21 +h- 2). These changes were accompanied by an increase in venous capacitance (2.46 +/- 0.16 to 3.99 +/- 0.24 c.c./100 c.c. of tissue). Along with a decrease in left ventricular filling pressure, cardiac index increased (1.99 +/- 0.13 to 2.37 +/- 0.15 L./min/M.2). No significant effect on heart rate was seen. Delta P/delta t, an index related to left ventricular dp/dt, increased in all but one patient (253 +/- 31 to 298 +/- 39 mm. Hg/sec.) (p less than 0.02 for all changes) in the face of decreased preload and afterload and unchanged heart rate, suggesting improved contractile state. A decrease in coronary blood flow (165 +/- 13 to 131 +/- 15 c.c./min.) and myocardial oxygen consumption (18.1 +/- 1.6 to 14.5 +/- 1.6 c.c./min.) was noted (p less than 0.02). No change in arterial-coronary sinus oxygen difference or lactate extraction was observed. These data demonstrate that the objectives of therapy in congestive heart failure, namely improved forward output and decreased ventricular filling pressures, can be achieved without metabolic deterioration by using sublingual isosorbide. The mechanisms responsible are related to diminished impedence to ventricular ejection and peripheral pooling of blood. Since the duration of action does not usually exceed 90 minutes, frequent drug administration may be a source of patient inconvience.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1163426     DOI: 10.1016/0002-8703(75)90324-5

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  20 in total

1.  Vasodilator treatment for acute and chronic heart failure.

Authors:  K Chatterjee; W W Parmley
Journal:  Br Heart J       Date:  1977-07

Review 2.  Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.

Authors:  S Silber
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Methods for the assessment of the effects of drugs on coronary blood flow in man.

Authors:  R H Swanton; D J Coltart
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

4.  Comparative haemodynamic and peripheral vasodilator effects of oral and chewable isosorbide dinitrate in patients with refractory congestive cardiac failure.

Authors:  J Figueras; W R Taylor; T Ogawa; J S Forrester; B N Singh; H J Swan
Journal:  Br Heart J       Date:  1979-03

Review 5.  Vasodilator therapy in the perioperative period.

Authors:  P N Fyman; J E Cottrell; L Kushins; P A Casthely
Journal:  Can Anaesth Soc J       Date:  1986-09

6.  Letter: Cardiac failure.

Authors:  N Pascal
Journal:  Br Med J       Date:  1976-08-28

7.  Peripheral oedema in patients treated with isosorbide dinitrate.

Authors:  J C Rodger
Journal:  Br Med J (Clin Res Ed)       Date:  1981-11-21

8.  Acute haemodynamic and metabolic effects of felodipine in congestive heart failure.

Authors:  A D Timmis; S Campbell; M J Monaghan; L Walker; D E Jewitt
Journal:  Br Heart J       Date:  1984-04

9.  Comparison of haemodynamic effects of oral hydralazine and prazosin hydrochloride in patients with chronic congestive heart failure.

Authors:  K Chatterjee; T A Ports; S Arnold; B Brundage; W Parmley
Journal:  Br Heart J       Date:  1979-12

10.  Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure.

Authors:  P W Armstrong
Journal:  Can Med Assoc J       Date:  1979-10-06       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.